Verastem, Inc. Segments Disclosure
12. Segment Reporting
The Company has one operating segment which is the business of researching, developing and commercializing drugs for the treatment of patients with cancer. While the Company group consists of entities incorporated in both the U.S. and Germany, the Company manages all business activities on a consolidated basis for the purposes of assessing performance, making operating decisions, and allocating Company resources. The Company’s Chief Operating Decision Maker (the “CODM”) is its President and Chief Executive Officer. The measure of segment assets is the same as reported on the consolidated balance sheets as total assets. The CODM assesses performance based on consolidated net loss that is also reported on the statements of operations and comprehensive loss. The CODM uses net loss to monitor budget versus actual results and to determine how to allocate resources and capital in line with the Company’s overall strategy and goals. The accounting policies of the Company's segment are the same as those described in Note 2. Significant accounting policies.
The table below is a summary of segment net loss including significant segment expenses for the years ended December 31, 2025, 2024 and 2023 (in thousands):
Year ended December 31, | |||||||||
2025 | | 2024 | | 2023 | |||||
Revenue: | |||||||||
Product revenue, net | $ | 30,914 | $ | — | — | ||||
Sale of COPIKTRA license and related assets | — | 10,000 | $ | — | |||||
Expenses: | |||||||||
Cost of sales - product | 4,600 | — | — | ||||||
Cost of sales - intangible amortization | 698 | — | — | ||||||
Research and development expenses(1) | 112,065 | 78,648 | 59,137 | ||||||
Commercial expenses(1) | 34,316 | 10,934 | 4,164 | ||||||
Medical affairs expenses(1) | 11,046 | 5,231 | 2,907 | ||||||
General and administrative expenses(1) | 28,512 | 21,785 | 19,755 | ||||||
Stock-based compensation expense | 9,405 | 7,342 | 5,860 | ||||||
Depreciation expense | 32 | 26 | 62 | ||||||
Interest income | (4,068) |
| (4,149) |
| (6,214) | ||||
Interest expense |
| 1,138 |
| 4,562 |
| 4,139 | |||
Loss on debt extinguishment | 1,826 | — |
| — | |||||
Change in fair value of preferred stock tranche liability | — | (4,189) | (2,751) | ||||||
Change in fair value of warrant liability | 27,492 | 19,149 | — | ||||||
Change in fair value of Notes | 12,751 | — | — | ||||||
Other segment items(2) | 572 | 1,113 | 308 | ||||||
Income tax expense | — | 185 | — | ||||||
Net loss | $ | (209,471) | $ | (130,637) | $ | (87,367) | |||
| (1) | This category is exclusive of non-cash stock-based compensation and severance expense. |
| (2) | Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations. |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 4, 2026 | Showing above |
| 2024 | Mar 20, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.